Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
REGN 
Regeneron Pharmaceuticals Inc (REGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: REGN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
25 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $716.78
1 Year Target Price $716.78
| 14 | Strong Buy |
| 5 | Buy |
| 5 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 10.85% | Avg. Invested days 49 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 59.99B USD | Price to earnings Ratio 14.27 | 1Y Target Price 716.78 |
Price to earnings Ratio 14.27 | 1Y Target Price 716.78 | ||
Volume (30-day avg) 25 | Beta 0.33 | 52 Weeks Range 476.49 - 1207.86 | Updated Date 08/15/2025 |
52 Weeks Range 476.49 - 1207.86 | Updated Date 08/15/2025 | ||
Dividends yield (FY) 0.31% | Basic EPS (TTM) 39.67 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-07-30 | When Before Market | Estimate 8.53 | Actual 12.89 |
Profitability
Profit Margin 31.37% | Operating Margin (TTM) 29.64% |
Management Effectiveness
Return on Assets (TTM) 6.66% | Return on Equity (TTM) 15.34% |
Valuation
Trailing PE 14.27 | Forward PE 15.53 | Enterprise Value 55221212548 | Price to Sales(TTM) 4.22 |
Enterprise Value 55221212548 | Price to Sales(TTM) 4.22 | ||
Enterprise Value to Revenue 3.88 | Enterprise Value to EBITDA 10.19 | Shares Outstanding 104170000 | Shares Floating 97911015 |
Shares Outstanding 104170000 | Shares Floating 97911015 | ||
Percent Insiders 1.93 | Percent Institutions 94.43 |
Upturn AI SWOT
Regeneron Pharmaceuticals Inc
Company Overview
History and Background
Regeneron Pharmaceuticals, Inc. was founded in 1988 by Leonard Schleifer and George Yancopoulos. Initially focused on nerve regeneration, it has evolved into a leading biopharmaceutical company discovering, developing, manufacturing, and commercializing medicines for serious diseases.
Core Business Areas
- Eye Diseases: Develops and commercializes treatments for eye diseases like macular degeneration and diabetic eye disease. Eylea is their flagship product in this segment.
- Inflammatory Diseases: Focuses on treatments for inflammatory conditions such as rheumatoid arthritis and atopic dermatitis. Dupixent is a key product in this segment.
- Oncology: Develops therapies for cancer, including checkpoint inhibitors and bispecific antibodies.
- Cardiovascular Disease: Develops therapies targeting cardiovascular risk factors.
Leadership and Structure
Leonard Schleifer is the founder, President, and CEO. George Yancopoulos is the co-founder, President, and Chief Scientific Officer. The company has a traditional corporate structure with executive leadership overseeing various functional areas.
Top Products and Market Share
Key Offerings
- Eylea (aflibercept): A VEGF inhibitor used to treat wet age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal diseases. It competes with Novartis's Lucentis and Roche's Vabysmo. Market share varies by region, but Eylea is a leading product in its class, generating billions in revenue. Revenue estimates were roughly $5.9B in 2023 for Regeneron alone.
- Dupixent (dupilumab): A monoclonal antibody used to treat atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. It's developed and commercialized in collaboration with Sanofi. Competitors include AbbVie's Rinvoq and Pfizer's Cibinqo. Dupixent's sales are substantial and continue to grow rapidly, with ~$11.58B in sales in 2023, shared between Sanofi and Regeneron
- Libtayo (cemiplimab): A PD-1 inhibitor used to treat certain types of skin cancer and lung cancer. Competitors include Merck's Keytruda and Bristol Myers Squibb's Opdivo. It generates several hundred million in revenue.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, stringent regulatory requirements, and intense competition. Key trends include personalized medicine, gene therapy, and immunotherapy.
Positioning
Regeneron is a leading innovator in biologics, with a strong pipeline and proven track record of developing successful drugs. Its competitive advantages include its VelocImmune antibody technology, strong research capabilities, and strategic partnerships.
Total Addressable Market (TAM)
The TAM for Regeneron's key therapeutic areas (eye diseases, inflammatory diseases, oncology) is estimated to be hundreds of billions of dollars globally. Regeneron is well-positioned to capture a significant share of this market with its innovative products.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities
- Proprietary technology platforms (e.g., VelocImmune)
- Successful commercialization track record
- Strategic partnerships (e.g., Sanofi)
- Experienced management team
Weaknesses
- Reliance on key products (e.g., Eylea, Dupixent)
- Patent expiration risks
- High R&D costs
- Competition from established pharmaceutical companies
Opportunities
- Expansion into new therapeutic areas
- Development of next-generation therapies
- Strategic acquisitions and collaborations
- Geographic expansion
- Growth in emerging markets
Threats
- Generic competition
- Biosimilar competition
- Regulatory changes
- Pricing pressures
- Clinical trial failures
Competitors and Market Share
Key Competitors
- NVS
- LLY
- MRK
- ABBV
- BMY
- PFE
- SNY
Competitive Landscape
Regeneron's advantages include its innovative technology platforms and strong R&D capabilities. Disadvantages include its reliance on key products and competition from larger pharmaceutical companies.
Major Acquisitions
Decibel Therapeutics
- Year: 2023
- Acquisition Price (USD millions): 109
- Strategic Rationale: Expanded Regeneron's gene therapy capabilities and pipeline in hearing loss disorders.
Growth Trajectory and Initiatives
Historical Growth: Regeneron has experienced significant growth in recent years, driven by the success of Eylea and Dupixent.
Future Projections: Analysts project continued revenue growth for Regeneron, driven by increased sales of Dupixent and potential new product launches. Future growth relies on successful clinical trials and regulatory approvals.
Recent Initiatives: Regeneron is investing heavily in R&D, including the development of new therapies for cancer and other diseases. The company is also pursuing strategic collaborations and acquisitions to expand its pipeline.
Summary
Regeneron is a strong biopharmaceutical company with innovative technology and a successful track record. Its key strengths lie in its R&D capabilities and blockbuster drugs like Eylea and Dupixent. However, it needs to diversify its product portfolio to mitigate reliance on its top sellers and monitor for competitive pressures and biosimilar threats. Overall, Regeneron is poised for continued growth, provided it maintains its innovation and navigates the evolving pharmaceutical landscape effectively.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Regeneron Pharmaceuticals Inc. SEC filings
- Analyst reports
- Industry publications
- Company website
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market data is subject to change. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Regeneron Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Tarrytown, NY, United States | ||
IPO Launch date 1991-04-02 | Co-Founder, President, CEO & Co-Chairman Dr. Leonard S. Schleifer M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 15182 | Website https://www.regeneron.com |
Full time employees 15182 | Website https://www.regeneron.com | ||
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.